Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD06-05 in Autoimmune Hematological Diseases
NCT07441525Phase 1Recruiting
- Start
- Feb 2026
- Primary completion
- Jan 2029
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RD06-05 in immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA) and Evans syndrome. Primary endpoints: Serious Adverse Events at 24 months, Treatment-Emergent Adverse Events at 24 months and 1 more. Started Feb 2026; status: recruiting.
02
Drugs
RD06-05
03
Conditions
immune thrombocytopenia (ITP)autoimmune hemolytic anemia (AIHA)Evans syndrome
Beyond the preview
Go deeper on NCT07441525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07441525.